Beyond Air reports flat $1.8 million quarterly revenue and reaffirms 2026 guidance
Beyond Air reported revenue of $1.8 million for the quarter ended June 30, 2026, unchanged from the prior-year quarter, while its net loss attributable to common stockholders widened to $7.9 million from $7.7 million. The company reaffirmed its calendar 2026 revenue guidance of $8 million and its 2027 guidance of $16-$18 million, and disclosed a financing of up to $30.1 million, including $10.2 million in upfront gross proceeds, which it said will fund international expansion and a U.S. launch pending FDA approval.
Key points
- Revenue was $1.8 million in both the quarter ended June 30, 2026 and the same quarter of 2025; gross margin rose to 13% from 9%.
- Net loss attributable to common stockholders was $7.9 million, or $11.00 per share, versus $7.7 million, or $30.67 per share, a year earlier; per-share figures reflect a one-for-twenty stock split in July 2026.
- Cash, cash equivalents, restricted cash and marketable securities totaled $15.2 million at June 30, 2026, before the financing of up to $30.1 million announced after quarter-end.
- The company said it regained compliance with Nasdaq's minimum bid price requirement and that the FDA review of the second-generation LungFit PH PMA supplement is pending, with approval expected in the second half of calendar 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.